Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months~* UACR 200 to 3000 mg/g~* eGFR ≥30 ml/min/1.73m2~* Treated with at least the minimal recommended dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both~Exclusion Criteria:~* History of Type 1 diabetes~* Women who are breast feeding~* Treatment with any uric acid-lowering therapy within previous 2 weeks~* History of intolerance to any XO (xanthine oxidase) inhibitor~* History of a gout flare requiring pharmacologic treatment~* History or presence of tophaceous gout~* History of immunosuppressant treatment for any known or suspected renal disorder~* History of a non-diabetic form of renal disease~* Glycosylated hemoglobin (HbA1c) \>11%~* sUA \<4.0 mg/dL or \>10.0 mg/dL~* Positive urinary pregnancy test~* Dialysis for acute renal failure within previous 6 months~* Renal allograft in place or a scheduled kidney transplant within the next 22 weeks~* Congenital or acquired solitary kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMX-049 40 mg QD (Once Daily) (Type: EXPERIMENTAL): TMX-049: 40 mg of TMX-049 to be taken orally, once daily
- TMX-049 200 mg QD (Once Daily) (Type: EXPERIMENTAL): TMX-049: 200 mg of TMX-049 to be taken orally, once daily
- TMX-049 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).